" "
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

About 1,000 Women Have Opted for PrenaTest® Since Market Launch

Published: Thursday, March 21, 2013
Last Updated: Thursday, March 21, 2013
Bookmark and Share
Over 150 prenatal diagnostic practices and clinics now offer the blood test for the detection of fetal trisomy 21.

In the first three months after market launch, close to 1,000 pregnant women have opted for the PrenaTest®, Europe's first non-invasive molecular genetic blood test for the detection of fetal trisomy 21.

All of them were at risk for trisomy 21 in the unborn child. The pregnant women were mainly from Germany, Austria and Switzerland, but also from other European countries.

Meanwhile over 150 qualified prenatal practices and clinics in Germany, Austria, Liechtenstein and Switzerland are now offering the PrenaTest®, more than twice as many as in August last year.

Several private health insurance companies in Germany have already reimbursed the cost for the PrenaTest®.

Evaluation of all PrenaTest® analyses carried out to date shows that the vast majority of 97 % of the tested women could be relieved with regard to the presence of trisomy 21 in their unborn child.

Only 1.5 % of the analyzed blood samples carried fetal trisomy 21. As far as known, these positive results have been confirmed by amniocentesis in accordance with the recommendations of the Bundesverband niedergelassener Pränatalmediziner (BVNP), the German Society of Human Genetics (gfh) as well as the International Society for Prenatal Diagnosis (ISPD).

Another 1.5 % of the blood samples could initially not be reported primarily due to a low amount of cell-free fetal DNA.

"These results clearly show how useful the PrenaTest® is in particular as a complement to the first trimester screening, because significantly less women actually need to undergo invasive testing and could be relieved quite early during their pregnancy," said Dr. Wera Hofmann, Chief Scientific Officer of LifeCodexx AG.

Dr. Hofmann continued, "Having this new method now established as a high quality lab routine process, we are currently working hard to further reduce the turnaround time between sample receipt and reporting. We aim to give the patient clarity as quickly as possible."

"The number of blood tests carried out until now shows that physicians increasingly trust the PrenaTest® as a guidance for the woman for or against an invasive diagnostic procedure," said Dr. Michael Lutz, Chief Executive Officer of LifeCodexx AG.

Dr. Lutz continued, "Soon the test will be able to reliably detect trisomies 13 and 18, too. Then the physician will be able to detect the three most common types of autosomal trisomy without any risk for the pregnant woman and her unborn child."

The PrenaTest® is the only non-invasive molecular genetic blood test for the detection of fetal trisomy 21 in Europe, which has successfully completed the conformity assessment procedures required for CE marking, thus proven its efficiency in terms of the in-vitro diagnostics directive of the European Union.

LifeCodexx is currently evaluating the expansion of test availability to other countries of the European Union.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Novel qPCR-based PrenaTest® Successfully Validated in Clinical Study
LifeCodexx AG’s cost-efficient NIPT assay to provide results on fetal trisomy 21 in 48 hours.
Thursday, December 03, 2015
PrenaTest® is Now Reimbursed by Swiss Statutory Health Insurance Programs
The first reimbursement worldwide of non-invasive prenatal tests by a national healthcare system.
Wednesday, July 08, 2015
PrenaTest® is Now Applicable for Multiple Pregnancies
To be generally applied after IVF, egg donation and other infertility treatments.
Tuesday, February 11, 2014
Improved PrenaTest® Provides Early Knowledge for High Risk Pregnancies
PrenaTest® can now be performed after the ninth week of pregnancy.
Wednesday, July 10, 2013
Scientific News
Preparing for Potential Zika Outbreaks
Experts at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) are developing tools to monitor the spread of the Zika virus and are conducting research to gather more solid data to better assess the risks associated with the infection.
What do Banana Peels and Human Skin Have in Common?
Human skin and banana peels have something in common: they produce the same enzyme when attacked. By studying fruit, researchers have come up with an accurate method for diagnosing the stages of this form of skin cancer.
Biomarker for Recurring HPV-Linked Oropharyngeal Cancers
A look-back analysis of HPV infection antibodies in patients treated for oropharyngeal (mouth and throat) cancers linked to HPV infection suggests at least one of the antibodies could be useful in identifying those at risk for a recurrence of the cancer, say scientists at the Johns Hopkins University.
Counting Cancer-busting Oxygen Molecules
Researchers from the Centre for Nanoscale BioPhotonics (CNBP), an Australian Research Centre of Excellence, have shown that nanoparticles used in combination with X-rays, are a viable method for killing cancer cells deep within the living body.
Genomic Signature Shared by Five Types of Cancer
National Institutes of Health researchers have identified a striking signature in tumor DNA that occurs in five different types of cancer.
Crowdfunding the Fight Against Cancer
From budding social causes to groundbreaking businesses to the next big band, crowdfunding has helped connect countless worthy projects with like-minded people willing to support their efforts, even in small ways. But could crowdfunding help fight cancer?
"Gene Fusion" Drives Childhood Brain Cancers
Study co-led by Penn scientists highlights potential targets for future cancer therapies.
Head Injury Patients Develop Brain Clumps Associated with Alzheimer’s Disease
Scientists have revealed that protein clumps associated with Alzheimer's disease are also found in the brains of people who have had a head injury.
New Way to Identify Brain Tumor Aggressiveness
Looking at a brain tumor’s epigenetic signature may help guide therapy.
OncoCyte, The Wistar Institute Enter Global Licensing Agreement
Exclusive rights to commercialize biomarker assay follows years of positive collaboration on lung cancer diagnostic test.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!